171 related articles for article (PubMed ID: 27845948)
1. 5-Fluorouracil degradation rate could predict toxicity in stages II-III colorectal cancer patients undergoing adjuvant FOLFOX.
Onesti CE; Botticelli A; La Torre M; Borro M; Gentile G; Romiti A; Lionetto L; Petremolo A; Occhipinti M; Roberto M; Falcone R; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Mar; 28(3):322-326. PubMed ID: 27845948
[TBL] [Abstract][Full Text] [Related]
2. Association of molecular markers with toxicity outcomes in a randomized trial of chemotherapy for advanced colorectal cancer: the FOCUS trial.
Braun MS; Richman SD; Thompson L; Daly CL; Meade AM; Adlard JW; Allan JM; Parmar MK; Quirke P; Seymour MT
J Clin Oncol; 2009 Nov; 27(33):5519-28. PubMed ID: 19858398
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of 5-fluorouracil degradation rate and Pharmacogenetic profiling to predict toxicity following adjuvant Capecitabine.
Roberto M; Romiti A; Botticelli A; Mazzuca F; Lionetto L; Gentile G; Paris I; Falcone R; Bassanelli M; Di Pietro FR; Onesti CE; Anselmi E; Macrini S; Simmaco M; Marchetti P
Eur J Clin Pharmacol; 2017 Feb; 73(2):157-164. PubMed ID: 27864592
[TBL] [Abstract][Full Text] [Related]
4. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
5. DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.
Nahid NA; Apu MNH; Islam MR; Shabnaz S; Chowdhury SM; Ahmed MU; Nahar Z; Islam MS; Islam MS; Hasnat A
Cancer Chemother Pharmacol; 2018 Jan; 81(1):119-129. PubMed ID: 29134491
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment evaluation of 5-fluorouracil degradation rate: association of poor and ultra-rapid metabolism with severe toxicity in a colorectal cancer patients cohort.
Mazzuca F; Borro M; Botticelli A; Mazzotti E; Marchetti L; Gentile G; La Torre M; Lionetto L; Simmaco M; Marchetti P
Oncotarget; 2016 Apr; 7(15):20612-20. PubMed ID: 26967565
[TBL] [Abstract][Full Text] [Related]
7. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147).
Lee AM; Shi Q; Pavey E; Alberts SR; Sargent DJ; Sinicrope FA; Berenberg JL; Goldberg RM; Diasio RB
J Natl Cancer Inst; 2014 Dec; 106(12):. PubMed ID: 25381393
[TBL] [Abstract][Full Text] [Related]
8. Methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms and FOLFOX response in colorectal cancer patients.
Etienne-Grimaldi MC; Milano G; Maindrault-Goebel F; Chibaudel B; Formento JL; Francoual M; Lledo G; André T; Mabro M; Mineur L; Flesch M; Carola E; de Gramont A
Br J Clin Pharmacol; 2010 Jan; 69(1):58-66. PubMed ID: 20078613
[TBL] [Abstract][Full Text] [Related]
9. A nomogram to predict 5-fluorouracil toxicity: when pharmacogenomics meets the patient.
Botticelli A; Onesti CE; Strigari L; Occhipinti M; Di Pietro FR; Cerbelli B; Petremolo A; Anselmi E; Macrini S; Roberto M; Falcone R; Lionetto L; Borro M; Milano A; Gentile G; Simmaco M; Marchetti P; Mazzuca F
Anticancer Drugs; 2017 Jun; 28(5):551-556. PubMed ID: 28296649
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and toxicity of adjuvant chemotherapy on colorectal cancer patients: how much influence from the genetics?
Duran G; Cruz R; Simoes AR; Barros F; Giráldez JM; Bernárdez B; Anido U; Candamio S; López-López R; Carracedo Á; Lamas MJ
J Chemother; 2020 Oct; 32(6):310-322. PubMed ID: 32441565
[TBL] [Abstract][Full Text] [Related]
11. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
12. The association of polymorphisms in folate-metabolizing genes with response to adjuvant chemotherapy of colorectal cancer.
Yousef AM; Zawiah M; Al-Yacoub S; Kadi T; Tantawi DA; Al-Ramadhani H
Cancer Chemother Pharmacol; 2018 Aug; 82(2):237-243. PubMed ID: 29845393
[TBL] [Abstract][Full Text] [Related]
13. Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients.
Sharma R; Hoskins JM; Rivory LP; Zucknick M; London R; Liddle C; Clarke SJ
Clin Cancer Res; 2008 Feb; 14(3):817-25. PubMed ID: 18245544
[TBL] [Abstract][Full Text] [Related]
14. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
Huang ZH; Hua D; Li LH
Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
[TBL] [Abstract][Full Text] [Related]
15. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
16. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group.
Schwab M; Zanger UM; Marx C; Schaeffeler E; Klein K; Dippon J; Kerb R; Blievernicht J; Fischer J; Hofmann U; Bokemeyer C; Eichelbaum M;
J Clin Oncol; 2008 May; 26(13):2131-8. PubMed ID: 18299612
[TBL] [Abstract][Full Text] [Related]
17. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity.
Cho HJ; Park YS; Kang WK; Kim JW; Lee SY
Ther Drug Monit; 2007 Apr; 29(2):190-6. PubMed ID: 17417073
[TBL] [Abstract][Full Text] [Related]
18. Predictors of survival and toxicity in patients on adjuvant therapy with 5-fluorouracil for colorectal cancer.
Gusella M; Frigo AC; Bolzonella C; Marinelli R; Barile C; Bononi A; Crepaldi G; Menon D; Stievano L; Toso S; Pasini F; Ferrazzi E; Padrini R
Br J Cancer; 2009 May; 100(10):1549-57. PubMed ID: 19384296
[TBL] [Abstract][Full Text] [Related]
19. A case-control study of a combination of single nucleotide polymorphisms and clinical parameters to predict clinically relevant toxicity associated with fluoropyrimidine and platinum-based chemotherapy in gastric cancer.
Cordova-Delgado M; Bravo ML; Cumsille E; Hill CN; Muñoz-Medel M; Pinto MP; Retamal IN; Lavanderos MA; Miquel JF; Rodriguez-Fernandez M; Liao Y; Li Z; Corvalán AH; Armisén R; Garrido M; Quiñones LA; Owen GI
BMC Cancer; 2021 Sep; 21(1):1030. PubMed ID: 34525956
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenetic studies on the prediction of efficacy and toxicity of fluoropyrimidine-based adjuvant therapy in colorectal cancer].
Kralovánszky J; Adleff V; Hitre E; Pap E; Réti A; Komlósi V; Budai B
Magy Onkol; 2007; 51(2):113-25. PubMed ID: 17660867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]